Port-Wine Stain: Clinical Trials

5 trials for Port-Wine Stain, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 withdrawn, 1 recruiting. 5 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Withdrawn 2, Recruiting 1
Phase 11Withdrawn 1

Follow Port-Wine Stain: new trials by email Literature Review of Port-Wine Stain trials Research Report on Port-Wine Stain

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT
Hemopfin+Green Light, Vehicle+Green Light - Port-wine Birthmarks, Port-Wine Stain
Phase 2RecruitingShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.842024-09-212026-03-03
Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study
Bosentan, Pulsed dye laser (PDL) - Port-wine Stains
Phase 2CompletedCentre Hospitalier Universitaire de Nice42014-04-012018-02-05
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Everolimus - Sturge Weber Syndrome
Phase 2WithdrawnBaylor College of Medicine2014-04-012016-05-05
Combined Use of Pulsed Dye Laser and Topical Antiangiogenic Agents for Treatment of Port Wine Stain Birthmarks
Topical Antiangiogenic, Pulsed Dye Laser - Port Wine Stain
Phase 1 / Phase 2WithdrawnUniversity of California, Irvine2009-11-012022-11-01
Measurement Skin Temperature During Pulsed Laser Exposure
cooling spray during laser treatment - Port-Wine Stain
Phase 2CompletedUniversity of California, Irvine1182002-07-012022-11-01

Narrower conditions

Epilepsy (1)  ·  Glaucoma (1)  ·  Sturge-Weber Syndrome (1)

Broader conditions

Congenital Abnormalities (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Skin Abnormalities (5)  ·  Skin Diseases (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Angiomatosis (1)  ·  Brain Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Eye Diseases (1)  ·  Hemangioma (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms, Vascular Tissue (1)  ·  Nervous System Diseases (1)

Interventions

Lasers, Dye (2)  ·  Angiogenesis Inhibitors (1)  ·  Bosentan (1)  ·  Everolimus (1)  ·  Laser Therapy (1)

Sponsors

University of California, Irvine (2)  ·  Baylor College of Medicine (1)  ·  Centre Hospitalier Universitaire de Nice (1)  ·  Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1)

Countries

United States (3)  ·  France (1)

Top investigators

Angus A Wilfong, MD (1)  ·  John S Nelson, M.D,PhD (1)  ·  John S. Nelson, M.D., Ph.D (1)